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Abstract
Vascular mineralization contributes to the high cardiovascular morbidity and mortality in patients who suffer from chronic
kidney disease and in individuals who have undergone solid organ transplantation. The immunosuppressive regimen used
to treat these patients appears to have an impact on vascular alterations. The effect of 6-mercaptopurine (6-MP) on vascular
calcification has not yet been determined. This study investigates the effect of 6-MP on vascular mineralization by the
induction of trans-differentiation of rat vascular smooth muscle cells in vitro. 6-MP not only induces the expression of osteo-
chondrocyte-like transcription factors and proteins but also activates alkaline phosphatase enzyme activity and produces
calcium deposition in in vitro and ex vivo models. These processes are dependent on 6-MP-induced production of reactive
oxygen species, intracellular activation of mitogen-activated kinases and phosphorylation of the transcription factor Cbfa1.
Furthermore, the metabolic products of 6-MP, 6-thioguanine nucleotides and 6-methyl-thio-inosine monophosphate have
major impacts on cellular calcification. These data provide evidence for a possible harmful effect of the immunosuppressive
drug 6-MP in vascular diseases, such as arteriosclerosis.
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Introduction
Pathological vascular changes and the subsequent high
incidence rates of non-fatal and fatal cardiovascular events are
major complications in patient cohorts with chronic renal failure
and in patients who have undergone successful kidney transplan-
tation [1,2]. The intima and media of the vessel wall may be
involved in mineralization, and changes at both sites can coexist.
Cardiovascular morbidity and mortality can increase due to
hemodynamic differences in the stiffened vessel [2]. Risk factors
that promote arteriosclerosis are similar to those known to cause
atherosclerosis and include high arterial blood pressure, diabetes
mellitus, advanced age and chronic kidney disease (CKD) [3–6].
Furthermore, there are several indications that oxidative stress
enhances the progression of vascular mineralization and arterio-
sclerosis [7,8].
At present, arteriosclerosis is validated as an active cell-
regulated process. One hypothesis for this process postulates that
a phenotypic transformation of vascular smooth muscle cells
(VSMCs) occurs. VSMCs are transformed into an osteo-chondro-
genic cell (OCC) phenotype. The cells then express OCC-specific
proteins, such as core-binding factor alpha 1 (Cbfa1) or alkaline
phosphatase (ALP) [9]. The OCCs then begin to release calcium
and phosphate, forming extracellular hydroxyapatite crystals. This
process is commonly referred to as calcification [6].
After successful renal transplantation, cardiovascular mortality
is lower compared to patients with end-stage renal disease, but
mortality is still increased compared to an age-matched population
with normal kidney function [1,10]. recent longitudinal study
elucidated that vascular calcification in kidney transplant patients
is substantial within four years [11]. There is a growing body of
direct and circumstantial evidence that immunosuppressive
therapy might influence the progression of vascular alterations
by affecting signaling pathways in multiple cell types [1]. Some
reports describe the influence of immunosuppressive drugs on the
overall cardiovascular outcome [1,12,13], but only limited
knowledge is available concerning the influence of immunosup-
pressive drugs on arteriosclerosis progression.
Among the commonly used immunosuppressive drugs investi-
gated, 6-mercaptopurine (6-MP) has the most prominent effect on
in vitro calcification. Here, we report that 6-MP induces
mineralization of VSMCs in in vitro and ex vivo models. 6-MP
stimulation leads increased calcium deposition resulting from its
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capacity to induce trans-differentiation of VSMCs into cells
expressing typical OCC markers. The induction of oxidative stress
by 6-MP and its metabolites is a major contributor to the calcifying
phenotype of VSMCs. The data reveal a possible harmful effect of
6-MP treatment that may enhance the progression of arterioscle-
rosis.
Methods
Please see Methods S1 for a detailed description of the methods
and protocols.
Animals and cell culture
All animal experiments were conducted under the guidelines of
the Protection of Animals. The protocol was approved by the
Berlin Ethics Committee of Animal Experiments, The Landesamt
fu¨r Gesundheit und Soziales, Berlin, Germany (permit number
O0212/02). Preparation of the aorta from Wistar rats was
accomplished under sodium pentobarbital anesthesia (400 mg/
kg body weight, intraperitoneal injection). All efforts were made to
minimize animal suffering. The adventitia of the rat aorta was
removed before further procedures were performed. The out-
growth technique was used for VSMC isolation from the rat aorta
[14]. The aorta was cut into rings for ex vivo assays.
Human VSMCs were purchased from PromoCell, where organ
preparation conformed to the Declaration of Helsinki. Cells in
passages 3 to 8 were used for experiments.
Induction of in vitro and ex vivo calcification
In vitro calcification of rat VSMCs and ex vivo calcification of
rat aortic rings were induced as described previously [15,16]. The
initial day of culture in CM (10 mmol/L b-glycerophosphate,
284 mmol/L ascorbic acid and 10 mmol/L sodium pyruvate) was
defined as day 0. The medium was replaced every 3 days.
Cell stimulation
Aortic rings and VSMCs were stimulated for short-term (24–
48 hours) or long-term (up to 21 days) experiments. In short-term
experiments using antagonists, cells were pre-treated for 30 min
with each antagonist.
Detection of mineralization
Alizarin Red staining was used to detect the mineralization
status of the aortic rings and VSMCs, and quantification of the
calcium content was determined either using the o-cresolphthalein
method or by measuring the ALP activity.
mRNA expression
After stimulation, cells were harvested for RNA isolation,
reverse transcription was performed, and mRNA expression was
determined via quantitative real-time PCR. mRNA expression
values were normalized to those of the house keeping gene b-actin.
Western blot
Protein lysates of VMSCs were separated into cytosolic and
nuclear fractions. The nuclear protein fraction was separated by
electrophoresis on a polyacrylamide gel, transferred to a poly-
vinylidene difluoride membrane, and incubated with specific
antibodies, including anti-Cbfa1, anti-Cbfa1-phospho-Ser465 and
anti-TATA-binding protein. For protein quantification, band
intensities of 3 blots from independent experiments were analyzed
using Bio1D-software (Vilber Lourmat).
Statistical analysis
Results are presented as means6SEM, and statistical signifi-
cance was determined by a Mann-Whitney test, unless otherwise
indicated. A P value ,0.05 was considered statistically significant.
Results
6-MP enhances mineralization in vitro and ex vivo
Previous studies have reported that medium containing b-
glycerophosphate (CM) can induce calcium deposition in VSMCs
[15]. This effect can be further increased by co-treatment with
dexamethasone (DEX) [9]. We tested other immunosuppressive
agents to determine if they could enhance calcium deposition.
Cyclosporin A, tacrolimus, and rapamycin did not increase CM-
induced calcium deposition after 21 days, whereas co-stimulation
with 6-MP and DEX led to a dramatic increase in calcium content
(Figure S1). Due to the prominent effect of 6-MP, we further
investigated its effect on VSMC mineralization in in vitro and ex
vivo models. 6-MP treatment for 21 days stimulated calcium foci
formation, which was visualized via Alizarin Red staining
(Figure 1A). Because 6-MP is known to have an anti-proliferative
effect on VSMCs [17], and the reduced cell numbers observed
with 6-MP treatment (Figure 1A), we measured cell viability/
proliferation. Long-term treatment with 6-MP for 7 to 21 days
reduced cell number relative to the controls in a dose-dependent
manner (Figure 1B). A bar graph with absorbance units for the
viability/proliferation assay is included as Figure S2. The calcium
content was quantified after decalcification of the cell layer. In this
analysis, the calcium content significantly increased upon 6-MP
treatment in control media and CM-cultured cells (Figure 1C). In
addition, ALP enzyme activity was significantly enhanced by 6-
MP compared to cells cultured in either control medium or CM
(Figure 1D). Interestingly, the increase in ALP enzyme activity was
higher upon 6-MP treatment in control media-stimulated cells
than in cells co-stimulated with CM. Therefore, ALP enzyme
activity was also measured after 7 days of treatment (Figure S3).
Here, 6-MP with or without CM co-treatment induced enzyme
activity similarly. To minimize species-specific effects, we also
tested the hypothesis on VSMCs from human donors. In human
VSMCs, ALP enzyme activity increased upon 6-MP treatment
(Figure S4). To test whether these effects could also be verified in
an ex vivo model, we incubated aortic rings from rats in either
control medium or CM in the presence or absence of 6-MP
(Figure 1E, F). Histological staining of aortic slices with Alizarin
Red revealed mineral deposition in the vessel media (Figure 1E). 6-
MP significantly increased the calcium content of the aortic rings
(Figure 1F).
6-MP promotes expression of osteogenic proteins
Mineralization of VSMCs is characterized by the expression of
osteogenic proteins [9,15]. We measured the expression of specific
genes after stimulation of VSMCs with 6-MP. 6-MP increased the
expression of the transcription factor cbfa1 in a dose-dependent
manner (Figure 2A). Furthermore, downstream gene products of
this transcription factor, such as ALP and osteocalcin (OCN), were
also induced by 6-MP (Figure 2B,C). Previous studies have noted
that cbfa1 is not only an initial transcription factor in osteoblast
differentiation but is also necessary for trans-differentiation of
VSMCs into calcifying cells [18]. Therefore, protein expression in
VSMCs was also investigated. Cbfa1 activity and DNA binding
depend on phosphorylation. Therefore, we measured Cbfa1 in the
nuclear protein fraction upon 6-MP treatment of VSMCs. 6-MP
increased Cbfa1 and Cbfa1-phospho contents in the nucleus in a
dose-dependent manner. TATA-binding protein was used as a
6-MP and Vascular Calcification
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loading control (Figure 2D). The bar graph in Figure 2D shows the
quantification of band intensity from 3 independent Western blots
of Cbfa1-phospho. Previous studies have shown that the mitogen-
activated kinases (MAPKs) MEK1 and ERK1/2 can phosphor-
ylate Cbfa1 [19]. Therefore, we investigated the effect of 6-MP on
MAPK phosphorylation. Phosphorylation of MEK1 and ERK1/2
was induced in a time-dependent manner upon 6-MP treatment
(Figure 2E). Inhibition of the kinases by U0126 diminished cbfa1
expression (Figure 2F).
Effects of 6-MP metabolites
6-MP is a cleavage product of azathioprine (AZA), and this
cleavage quickly occurs either non-enzymatically [20] or enzy-
matically via glutathione S-transferase (GST) [21]. Subsequently,
different enzymatic pathways lead to further conversion of 6-MP,
including the xanthine oxidase (XO), thiopurinemethyltransferase
(TPMT) and hypoxanthine guanine phosphoribosyltransferase
(HPRT1) pathways (Figure 3A) [22]. XO metabolizes more than
80% of 6-MP into 6-thio-uric acid (6-TU), and the remaining
amount can be further catabolically and anabolically converted
into metabolites [23]. The required enzymes for 6-MP metabolism
are expressed in rat VSMCs (Figure 2B). Because the majority of
6-MP is metabolized via XO [21], we blocked this pathway and
measured the effect on mineralization. As XO is a known source of
reactive oxygen species (ROS), we used the inhibitors allopurinol
(XO inhibitor) and tiron as scavengers for ROS [24]. To examine
the effect of XO inhibition in the mineralization process, we used
both inhibitors during co-stimulation with 6-MP. Allopurinol
treatment resulted in a reduction of ALP expression and
significantly diminished its enzymatic activity, while co-treatment
with tiron significantly diminished both ALP expression and
enzyme activity (Figure 3C,D).
To determine the effect of 6-MP metabolites on calcification of
VSMCs, we examined the three main metabolites of 6-MP: 6-TU,
6-thio-guanine nucleotides (6-TGNs) and 6-methyl-thio-inosine
monophosphate (6-MTIMP). All investigated 6-TGNs (6-T-GMP,
-GDP, -GTP) and 6-MTIMP, significantly induced cbfa1 and
ALP mRNA expression, whereas 6-TU produced no change in
expression (Figure 3E,F). This phenomenon could be verified by
measuring calcium content and ALP activity after 21 days in
culture. With the exception 6-TU, all investigated compounds (6-
TGNs and 6-MTIMP) robustly induced calcium deposition
(Figure 3G) and ALP enzyme activity (Figure 3H).
6-MP promotes the production of ROS
6-TU is the main metabolite of 6-MP conversion. Inhibition of
this pathway by allopurinol and tiron reduced mineralization, but
6-TU itself seemed to have no effect on calcification. Therefore,
the metabolic pathway and associated ROS production might be
relevant. Previous evidence suggests that the ROS level might
contribute to VSMC mineralization [7,8]. Here, we used several
specific probes, in particular superoxide and hydrogen peroxide, to
detect ROS levels after treatment of VSMCs with 6-MP and its
metabolites. 6-MP increased the production of superoxide in
dihydroethidium (DHE)-labeled cells in a dose-dependent manner,
as shown by representative fluorescence microscopy images
(Figure 4A) and quantification using a 96-well assay (Figure 4B).
Superoxide is rapidly converted to hydrogen peroxide. Therefore,
we measured its production via flow cytometry (Figure 4C,D).
Stimulation of cells with the 6-TGNs and 6-MTIMP also
Figure 1. 6-MP-induced calcification in vitro and ex vivo. (A–D) VSMCs were cultured in control medium or CM66-MP (100 mmol/L) for 21 days.
(A) Mineral deposits were visualized via Alizarin red staining. One representative experiment is shown (n = 5). (B) VSMCs were treated with 6-MP
(1 mmol/L–1 mmol/L) for up to 21 days and viability/proliferation was measured. (C) Calcium content (n.6) or (D) ALP enzyme activity (n.6) was
quantified and normalized to protein content. (E,F) Rat aortic rings were incubated in control medium or CM 6 6-MP (100 mmol/L) for 14 days. (E)
One aortic ring treated with each type of stimulation was used for histochemical analysis. Slices were stained with Alizarin Red to visualize calcium
deposition. (F) Calcium content was quantified and normalized to the dry weight of aortic rings (n.6). Data represent means6SEM, *p,0.05 vs.
control. #p,0.05 vs. CM. ALP: alkaline phosphatase, CM: calcifying medium, 6-MP: 6-mercaptopurine.
doi:10.1371/journal.pone.0101709.g001
6-MP and Vascular Calcification
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significantly increased superoxide production, whereas 6-TU
seemed to have no effect on superoxide production (Figure 4E).
Inhibition of XO by allopurinol or tiron treatment diminished the
6-MP-induced production of superoxide (Figure 4F).
Discussion
In this study, we report that 6-MP, a cleavage product of the
immunosuppressive drug AZA, is a potent inducer of vascular
calcification in in vitro and ex vivo models. 6-MP stimulated trans-
differentiation of VSMCs into an OCC phenotype, which has
been proposed as one hypothesis for vascular mineralization [18].
The generation of ROS by 6-MP could contribute to the
mechanism responsible for the trans-differentiation of VSMCs.
These data unmask a potential harmful effect of 6-MP
treatment for vascular disease and specifically focus on the
progression of the vascular calcification observed in arteriosclero-
sis. AZA is commonly used, as it is a potent drug that controls
many immune diseases [25,26]. During the last several years, AZA
treatment has been replaced in patients who have undergone solid
organ transplantation [20,25]. However, AZAs still routinely used
in the treatment of several auto-immune diseases [26–28].
Currently, its application as an immunosuppressive drug has
increased due to its beneficial effects on lipid profiles and
fibrinolytic parameters [12,29,30]. However, there are several
indications that the cardiovascular risk in AZA-treated patients is
increased [27,28], and vascular alterations could occur. The
present study gives additional indications of the potentially
harmful effects.
Some clinical studies have revealed relevant roles for immuno-
suppressive drugs on cardiovascular risk profiles [1,12,13,31].
Reasons for the increased cardiovascular morbidity and mortality
are multi-factorial, but there are clear reports that immunosup-
pressive drugs used to control the aforementioned diseases might
influence the occurrence of cardiovascular events [12]. Vascular
alterations and the incidence rates of non-fatal and fatal
cardiovascular events are some of the major complications in
different patient cohorts, such as patients suffering from rheuma-
toid arthritis (RA) or systemic lupus erythematosus (SLE) [32],
dialysis patients or patients who have undergone solid organ
transplantation, especially kidney transplant patients (KTX)
[1,2,33]. Upon AZA treatment, the risk of coronary heart disease
increases in patients with SLE [27] and in KTX [31] and RA
patients [28].
Generally, it has been thought that the underlying disease might
induce a high cardiovascular burden in these patient groups.
Figure 2. mRNA expression of osteogenic proteins. (A–C) VSMCs were stimulated with 6-MP as indicated and mRNA expression was detected
after 48 h. Data represent means6SEM, n$6,*p,0.05 vs. control. (D) VSMCs were stimulated with 6-MP for 48 h. Nuclear proteins were extracted.
Cbfa1, Cbfa1-phospho and TATA-bp were detected via Western blot. Representative images and relative band intensities of 3 independent blots of
Cbfa1-phospho are shown. (E) MEK1 and ERK1/2 activation was detected via Bio-Plex (n$6). Values are given as % of control and are normalized to
total kinase. (F) mRNA expression of cbfa1 after 48 h treatment with 6-MP (100 mmol/L)6 U0126 (1 mmol/L) (n.6). Data represent means6SEM, *p,
0.05 vs. control. ALP: alkaline phosphatase, cbfa1: core binding factor alpha-1, 6-MP: 6-mercaptopurine, OCN: osteocalcin.
doi:10.1371/journal.pone.0101709.g002
6-MP and Vascular Calcification
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However, given the present results, it is possible that AZA
contributes to the higher cardiovascular risk. One report states
that AZA may have atheroprotective properties [34]. In this study,
the authors demonstrated that in a hypercholesterolemic apoE
transgenic mouse model, local delivery of 6-MP reduced
atherosclerosis, mainly due to reduced activation of monocytes
[34]. This effect has not yet been demonstrated by systemic
application. Studies in dialysis [35,36] and KTX patients [37–39]
have shown that vessel calcification due to arteriosclerosis, rather
than atherosclerosis, strongly predicts all-cause mortality and
cardiovascular disease.
The results of the present study demonstrate that 6-MP induces
the expression of typical bone cell markers that induce mineral-
ization in VSMCs. To our knowledge, this report is the first that
examines the role of 6-MP with respect to vascular calcification. In
the in vitro model used, 6-MP produces a stronger effect on
calcium deposition in compared with DEX treatment, which has
demonstrated a calcification-inducing effect in previous experi-
mental studies [9]. This effect could be verified by measuring the
calcium deposition and enzyme activity of ALP in rat and human
VSMCs. Similarly, 6-MP treatment results in mineralization of the
vessel media in ex vivo experiments. The less potent effect of 6-MP
in aortic rings compared with its effect in vitro might be due to
experimental differences between isolated VSMCs and VSMC
tissue cells. To verify the observed effects of 6-MP, the expression
levels of certain proteins were investigated. The osteogenic
transcription factor, cbfa1, and downstream osteogenic proteins,
such as OCN, were induced by 6-MP treatment. Cbfa1 is an initial
transcription factor in osteogenic differentiation and also appears
to play a relevant role in VSMC transformation [18]. We found
evidence of induction of the Cbfa1 protein and a phospho variant
in VSMCs. Inhibition of ERK1/2 led to decreased cbfa1 mRNA
expression. This results supports the known auto-regulatory
function of cbfa1 expression [40].
AZA is rapidly converted to 6-MP either non-enzymatically
[20] or enzymatically, via GST [21]. Subsequently, 6-MP is
enzymatically cleaved into three main metabolites, including 6-
TU, 6-MTIMP and 6-TGNs (Figure 3A), which act as pharma-
cological agents [21]. Here, we investigated these three main
metabolites. The investigated concentrations of all metabolites
were similar, as expected in the humans after AZA treatment [22].
All 6-TGNs and 6-MTIMP significantly induced osteogenic
expression and VSMC mineralization, as detected by calcium
deposition and ALP activity. The main metabolite of 6-MP is 6-
TU (.80%) [23]. As we have shown here, 6-TU had no effect on
vascular calcification, although inhibition of the metabolism of 6-
MP to 6-TU via XO reduced calcification. This observation led us
to the question, if ROS production, via XO, might be involved
[24,41]. ROS is capable of inducing vascular mineralization
[8,42,43]. A very similar effect has been previously observed in
which activation of XO resulted in the progression of vascular cells
to calcifying cells [42]. Furthermore, previous reports show that
AZA/6-MP influences oxidative stress [44,45]. 6-MP is degraded
to 6-TGNs and other metabolites, which, with the exception of 6-
TU effect vascular calcification and oxidative stress. ROS might
contribute to various mechanisms that induce the mineralization
phenotype of VSMCs. Further studies investigating the down-
stream signaling pathways are necessary to describe the effects of
the different 6-MP metabolites on vascular calcification.
Figure 3. Effects of 6-MP metabolites. (A) Metabolism scheme of the prodrug AZA. (B) Expression of Xdh (351 bp), HPRT1 (168 bp), IMPDH1
(505 bp), TPMT (104 bp), and b-actin (76 bp) in unstimulated VSMCs. (C,D) Effect of 6-MP (100 mmol/L), allopurinol (5 mmol/L) and tiron (100 mmol/L)
stimulation on VSMC (C) ALP mRNA expression and (D) ALP enzyme activity. Enzyme activity was normalized to the protein content of the cells. Data
represents means6SEM, n$6, *p,0.05 vs. control #p,0.05 vs. 6-MP. (E,F) VSMCs were stimulated with 6-MP (100 mmol/L), 6-TGNs (each 10 mmol/L),
6-MTIMP (10 mmol/L) or 6-TU (10 mmol/L) for 48 h and (E) cbfa1, and (F) ALP mRNA expression levels were analyzed. Data represents means6SEM,
n$6, *p,0.05 vs. control. (G,H) VSMCs were incubated as indicated (100 mmol/L 6-MP, 6-TGNs [each 10 mmol/L], 6-MTIMP or 6-TU [each 10 mmol/L]
for 21 days) and (G) calcium content and (H) ALP enzyme activity were measured. Data represents means6SEM, n$6,*p,0.05 vs. control. AZA:
azathioprine, cbfa1: core binding factor alpha-1, GST: glutathione S-transferase, HPRT: hypoxanthine guanine phosphoribosyltransferase, IMPDH1:
inosine monophosphate dehydrogenase 1, 6-MP: 6-mercaptopurine, 6-MTIMP: 6-methylthioinosine monophosphate, 6-TGDP: 6-thioguanosine
diphosphate, 6-TGMP: 6-thioguanosine monophosphate, 6-TGNs: 6-thioguanine nucleotides, 6-TGTP: 6-thioguanosine triphosphate, 6-TIMP: 6-
thioinosine monophosphate, TPMT: thiopurinemethyltransferase, 6-TU: 6-thiouric acid, Xdh: Xanthine dehydrogenase, XO: xanthine oxidase.
doi:10.1371/journal.pone.0101709.g003
6-MP and Vascular Calcification
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Figure 4. Involvement of ROS. (A,B,E,F) VSMCs were stimulated as indicated for 30 min before labeling cells with DHE. Superoxide production was
(A) visualized via fluorescence microscopy (representative images from 3 independent experiments) or (B,E,F) quantified in a fluorescence plate
reader (n$6). (C,D) Hydrogen peroxide production is measured in H2DCFDA-labeled cells via flow cytometry. (C) Representative histograms of flow
data (grey: control, white: 6-MP). (D) Quantification of fluorescence intensity by % of labeled control (n$6). (E) Stimulation with 6-MP (100 mmol/L) or
its metabolites (each 10 mmol/L). (F) Stimulation with 6-MP (100 mmol/L) alone or costimulation with inhibitors (tiron [1 mmol/L] and allopurinol
[1 mmol/L]). DHE: dihydroethidium, 6-MP: 6-mercaptopurine, 6-MTIMP: 6-methylthioinosine monophosphate, 6-TGDP: 6-thioguanosine diphosphate,
6-TGMP: 6-thioguanosine monophosphate, 6-TGN: 6-thioguanine nucleotide, 6-TGTP: 6-thioguanosine triphosphate, 6-TU: 6-thiouric acid.
doi:10.1371/journal.pone.0101709.g004
6-MP and Vascular Calcification
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In conclusion, this study provides evidence that 6-MP intake
over an extended period of time in patients who undergo organ
transplantation or suffer from autoimmune diseases might have
harmful effects that may contribute to the progression of vascular
mineralization. Nonetheless, the study has some limitations. We
used in vitro and ex vivo models to show the impact of 6-MP on
vascular calcification. 6-MP has anti-proliferative properties on
VSMCs and decreases cell number over time relative to the un-
stimulated cells. At concentrations of 6-MP between 100 mmol/L
to 1 mmol/L, an inhibition of cell proliferation was observed. Most
of the experiments in this study were carried out with an expected
non-toxic 6-MP concentration (100 mmol/L). At the current stage,
the influence of 6-MP-induced cell death or perhaps cell migration
in a calcification nidus on the mineralization process in vitro,
cannot be excluded. Animal studies and clinical prospective and
retro-prospective trials are necessary to describe the effects of long-
term treatment with AZA/6-MP. In humans, confounding factors,
such as disease duration and disease severity, and other
therapeutics might have a major influence on the progression of
the calcification process. If this possibility is indeed confirmed, 6-
MP therapy in any context should be examined to reduce possible
harmful long-term cardiovascular effects.
Supporting Information
Figure S1 Influence of immunosuppressive drugs on in
vitro mineralization. rVSMCs were cultured in control
medium (white bar graph) or CM (black bar graphs) in the
presence or absence of DEX (100 nmol/L), CYA, (100 nmol/L),
FK506 (10 nmol/L), RPA (1 nmol/L), and 6-MP (100 mmol/L).
Calcium deposition was quantified after 21 days and normalized
to protein content of the cells. Data represent means6SEM, n$6,
*p,0.05 vs. control, #p,0.05 vs. CM. CM: calcification medium,
CYA: cyclosporin A, DEX: dexamethasone, FK506: tacrolimus,
RPA: rapamycin, 6-MP: 6-mercaptopurine, VSMCs: vascular
smooth muscle cells.
(JPG)
Figure S2 Cell viability/proliferation. rVSMCs were
cultured in control medium in the presence or absence of 6-MP
(1 mmol/L–1 mmol/L) for 1 to 21 days. Data represent mean-
s6SEM, *p,0.05 vs. control, 6-MP: 6-mercaptopurine, VSMCs:
vascular smooth muscle cells.
(JPG)
Figure S3 ALP enzyme activity after 7 days of treat-
ment. rVSMCs were cultured in control medium or calcification
medium in the presence or absence of 6-MP (100 mmol/L). ALP
enzyme activity, normalized to protein content, was detected after
7 d of treatment. Data represent means6SEM, n=8, *p,0.05 vs.
control, #p,0.05 vs. CM. ALP: alkaline phosphatase, 6-MP: 6-
mercaptopurine, VSMCs: vascular smooth muscle cells.
(JPG)
Figure S4 Mineralization of human VSMCs. hVSMCs
were cultured in control medium or calcification medium in the
presence or absence of 6-MP (100 mmol/L). ALP enzyme activity,
normalized to protein content of the cells, was detected after 14 d
of incubation. Data represent means6SEM, n=3, *p,0.05 vs.
control. ALP: alkaline phosphatase, CM: calcifying medium, 6-





Table S1 Primer sequences.
(PDF)
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